- Previous Close
6.18 - Open
6.14 - Bid 6.14 x 100
- Ask 6.23 x 100
- Day's Range
6.07 - 6.43 - 52 Week Range
4.26 - 12.83 - Volume
379,515 - Avg. Volume
551,614 - Market Cap (intraday)
441.281M - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
5.15 - EPS (TTM)
1.20 - Earnings Date Mar 10, 2025 - Mar 14, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Mar 25, 2024
- 1y Target Est
--
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
www.siga.com45
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: SIGA
View MorePerformance Overview: SIGA
Trailing total returns as of 12/16/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SIGA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SIGA
View MoreValuation Measures
Market Cap
441.28M
Enterprise Value
342.55M
Trailing P/E
5.15
Forward P/E
4.93
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.56
Price/Book (mrq)
2.60
Enterprise Value/Revenue
1.97
Enterprise Value/EBITDA
3.26
Financial Highlights
Profitability and Income Statement
Profit Margin
49.33%
Return on Assets (ttm)
36.95%
Return on Equity (ttm)
58.39%
Revenue (ttm)
173.73M
Net Income Avi to Common (ttm)
85.71M
Diluted EPS (ttm)
1.20
Balance Sheet and Cash Flow
Total Cash (mrq)
99.27M
Total Debt/Equity (mrq)
0.89%
Levered Free Cash Flow (ttm)
54.24M